Symbol | Exchange | Currency |
|---|
Chimeric Therapeutics Limited researches, develops, and commercializes cell therapies for cancer in Australia. The company develops CLTX CAR T cell therapy that is in Phase I clinical study for Glioblastoma; and CDH17 CAR T, which is in preclinical study for neuroendocrine tumours, as well as colorectal, pancreatic, and gastric cancer. It has a strategic partnership with OncoBay Clinical for the development program of CLTX CAR T. The company was incorporated in 2020 and is based in Carlton, Australia.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Neutral | Neutral | Neutral | Sell | Strong Sell |
| Summary | Sell | Sell | Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 91.99 | 94.48 | 89.54 | +5.51 | +6.37% | 27.04M | NYSE | |||
| 38.35 | 38.85 | 37.64 | +0.84 | +2.24% | 9.03M | NYSE | |||
| 47.14 | 47.48 | 44.52 | +2.89 | +6.53% | 5.09M | NYSE | |||
| 26.92 | 26.92 | 26.92 | +0.29 | +1.07% | 351.00 | NYSE | |||
| 8.29 | 8.44 | 8.14 | +0.16 | +1.97% | 6.54M | NYSE | |||
| 115.90 | 117.10 | 113.07 | +3.30 | +2.93% | 6.00M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 1.19 | 1.20 | 1.11 | +0.1000 | +9.17% | 10.48M | NYSE | |||
| 0.18 | 0.18 | 0.171 | +0.0073 | +4.23% | 1.45M | NYSE | |||
| 102.47 | 103.20 | 97.54 | +8.23 | +8.73% | 163.11M | NASDAQ | |||
| 174.46 | 175.68 | 172.58 | -1.01 | -0.58% | 4.99M | NASDAQ | |||
| 19.43 | 19.60 | 19.33 | +0.30 | +1.57% | 550.91K | NYSE | |||
| 0.226 | 0.24 | 0.221 | -0.001 | -0.57% | 1.06M | NASDAQ | |||
| 9.53 | 9.63 | 9.25 | +0.32 | +3.47% | 506.60K | NASDAQ | |||
| 128.62 | 129.34 | 126.75 | +2.07 | +1.64% | 3.64M | NASDAQ |